EU/3/19/2200

About

On 21 August 2019, orphan designation EU/3/19/2200 was granted by the European Commission to Dr Sebastian Canisius, Germany, for clofazimine for the treatment of nontuberculous mycobacterial lung disease.

Key facts

Active substance
Clofazimine
Disease / condition
Treatment of nontuberculous mycobacterial lung disease
Date of first decision
21/08/2019
Outcome
Positive
EU designation number
EU/3/19/2200

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Dr Sebastian Canisius
Hohmannsweg 8
35085 Ebsdorfergrund
Germany
Tel. +491776377778
E-mail: info@qrumpharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating